Merck Stock (MRK) in November 2025: Price, Latest News, Forecasts and Analyst Outlook
Merck & Co. (NYSE: MRK) is ending November 2025 on a strong note. A flurry of regulatory wins for cancer drug Keytruda, positive mid‑stage data for heart drug Winrevair, and fresh deal‑making have pushed the share price close to its